182 related articles for article (PubMed ID: 19927009)
1. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae.
Fedorova OV; Tapilskaya NI; Bzhelyansky AM; Frolova EV; Nikitina ER; Reznik VA; Kashkin VA; Bagrov AY
J Hypertens; 2010 Feb; 28(2):361-6. PubMed ID: 19927009
[TBL] [Abstract][Full Text] [Related]
2. DigiFab interacts with endogenous cardiotonic steroids and reverses preeclampsia-induced Na/K-ATPase inhibition.
Ishkaraeva-Yakovleva VV; Fedorova OV; Solodovnikova NG; Frolova EV; Bzhelyansky AM; Emelyanov IV; Adair CD; Zazerskaya IE; Bagrov AY
Reprod Sci; 2012 Dec; 19(12):1260-7. PubMed ID: 22649120
[TBL] [Abstract][Full Text] [Related]
3. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia.
Lopatin DA; Ailamazian EK; Dmitrieva RI; Shpen VM; Fedorova OV; Doris PA; Bagrov AY
J Hypertens; 1999 Aug; 17(8):1179-87. PubMed ID: 10466474
[TBL] [Abstract][Full Text] [Related]
4. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia.
Averina IV; Tapilskaya NI; Reznik VA; Frolova EV; Fedorova OV; Lakatta EG; Bagrov AY
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):19-23. PubMed ID: 17535731
[TBL] [Abstract][Full Text] [Related]
5. Endogenous cardiotonic steroids in chronic renal failure.
Kolmakova EV; Haller ST; Kennedy DJ; Isachkina AN; Budny GV; Frolova EV; Piecha G; Nikitina ER; Malhotra D; Fedorova OV; Shapiro JI; Bagrov AY
Nephrol Dial Transplant; 2011 Sep; 26(9):2912-9. PubMed ID: 21292813
[TBL] [Abstract][Full Text] [Related]
6. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia.
Fedorova OV; Ishkaraeva VV; Grigorova YN; Reznik VA; Kolodkin NI; Zazerskaya IE; Zernetkina V; Agalakova NI; Tapilskaya NI; Adair CD; Lakatta EG; Bagrov AY
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104471
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension.
Fedorova OV; Simbirtsev AS; Kolodkin NI; Kotov AY; Agalakova NI; Kashkin VA; Tapilskaya NI; Bzhelyansky A; Reznik VA; Frolova EV; Nikitina ER; Budny GV; Longo DL; Lakatta EG; Bagrov AY
J Hypertens; 2008 Dec; 26(12):2414-25. PubMed ID: 19008721
[TBL] [Abstract][Full Text] [Related]
8. Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods.
Pullen MA; Harpel MR; Danoff TM; Brooks DP
J Immunol Methods; 2008 Jul; 336(2):235-41. PubMed ID: 18555269
[TBL] [Abstract][Full Text] [Related]
9. Role of endogenous digitalis-like factors in the clinical manifestations of severe preeclampsia: a sytematic review.
Buckalew VM
Clin Sci (Lond); 2018 Jun; 132(12):1215-1242. PubMed ID: 29930141
[TBL] [Abstract][Full Text] [Related]
10. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake.
Fedorova OV; Kolodkin NI; Agalakova NI; Namikas AR; Bzhelyansky A; St-Louis J; Lakatta EG; Bagrov AY
J Hypertens; 2005 Apr; 23(4):835-42. PubMed ID: 15775789
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and exogenous cardiac glycosides and their mechanisms of action.
Schoner W; Scheiner-Bobis G
Am J Cardiovasc Drugs; 2007; 7(3):173-89. PubMed ID: 17610345
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure.
Haller ST; Kennedy DJ; Shidyak A; Budny GV; Malhotra D; Fedorova OV; Shapiro JI; Bagrov AY
Am J Hypertens; 2012 Jun; 25(6):690-6. PubMed ID: 22378033
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.
Pullen MA; Brooks DP; Edwards RM
J Pharmacol Exp Ther; 2004 Jul; 310(1):319-25. PubMed ID: 14982968
[TBL] [Abstract][Full Text] [Related]
14. Magnesium sulfate potentiates effect of DigiFab on marinobufagenin-induced Na/K-ATPase inhibition.
Zazerskaya IE; Ishkaraeva VV; Frolova EV; Solodovnikova NG; Grigorova YN; David Adair C; Fedorova OV; Bagrov AY
Am J Hypertens; 2013 Nov; 26(11):1269-72. PubMed ID: 23878005
[TBL] [Abstract][Full Text] [Related]
15. Analytical aspects of marinobufagenin.
Lenaerts C; Demeyer M; Gerbaux P; Blankert B
Clin Chim Acta; 2013 Jun; 421():193-201. PubMed ID: 23470428
[TBL] [Abstract][Full Text] [Related]
16. Involvement of marinobufagenin in a rat model of human preeclampsia.
Vu HV; Ianosi-Irimie MR; Pridjian CA; Whitbred JM; Durst JM; Bagrov AY; Fedorova OV; Pridjian G; Puschett JB
Am J Nephrol; 2005; 25(5):520-8. PubMed ID: 16179779
[TBL] [Abstract][Full Text] [Related]
17. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.
Bagrov AY; Shapiro JI; Fedorova OV
Pharmacol Rev; 2009 Mar; 61(1):9-38. PubMed ID: 19325075
[TBL] [Abstract][Full Text] [Related]
18. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
[TBL] [Abstract][Full Text] [Related]
19. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries.
Nikitina ER; Mikhailov AV; Nikandrova ES; Frolova EV; Fadeev AV; Shman VV; Shilova VY; Tapilskaya NI; Shapiro JI; Fedorova OV; Bagrov AY
J Hypertens; 2011 Apr; 29(4):769-76. PubMed ID: 21330936
[TBL] [Abstract][Full Text] [Related]
20. Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease.
Haller ST; Drummond CA; Yan Y; Liu J; Tian J; Malhotra D; Shapiro JI
Am J Hypertens; 2014 Apr; 27(4):603-9. PubMed ID: 24014658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
